A possible role for methotrexate in the treatment of childhood acute myeloid leukaemia, in particular for acute monocytic leukaemia.

[1]  M. Relling,et al.  TOPOISOMERASE II INHIBITOR‐RELATED ACUTE MYELOID LEUKAEMIA , 2000, British journal of haematology.

[2]  G. Peters,et al.  Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates. , 1999, Blood.

[3]  M. Grever,et al.  Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. , 1999, Blood.

[4]  M. Rots,et al.  Cellular drug resistance in acute myeloid leukemia: literature review and preliminary analysis of an ongoing collaborative study. , 1999, Klinische Padiatrie.

[5]  G. Peters,et al.  MRP3, an organic anion transporter able to transport anti-cancer drugs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[6]  G. Peters,et al.  Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. , 1999, Cancer research.

[7]  M. Rots,et al.  Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. , 1999, Blood.

[8]  G. Peters,et al.  Differential Methotrexate Resistance in Childhood T- Versus Common/PreB-Acute Lymphoblastic Leukemia Can Be Measured by an In Situ Thymidylate Synthase Inhibition Assay, But Not by the MTT Assay , 1999 .

[9]  G. Peters,et al.  A Structurally Altered Human Reduced Folate Carrier with Increased Folic Acid Transport Mediates a Novel Mechanism of Antifolate Resistance* , 1998, The Journal of Biological Chemistry.

[10]  M. Rots,et al.  Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  J. Rowe.  What is the best induction regimen for acute myelogenous leukemia? , 1998, Leukemia.

[12]  R. Gray,et al.  Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trial , 1998 .

[13]  R. Pieters,et al.  Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. , 1998, Blood.

[14]  J. Bertino,et al.  gamma-Glutamyl hydrolase and folylpolyglutamate synthetase activities predict polyglutamylation of methotrexate in acute leukemias. , 1997, Oncology research.

[15]  J. Bertino,et al.  Disparate affinities of antifolates for folylpolyglutamate synthetase from human leukemia cells , 1997 .

[16]  M. Mazumdar,et al.  Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. , 1997, Blood.

[17]  M. Spinella,et al.  Comparison of methotrexate polyglutamylation in L1210 leukemia cells when influx is mediated by the reduced folate carrier or the folate receptor. Lack of evidence for influx route-specific effects. , 1996, Biochemical pharmacology.

[18]  J. Buckley,et al.  Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. , 1996, Blood.

[19]  J. Korenberg,et al.  Purification and Properties of Human Cytosolic Folylpoly-γ-glutamate Synthetase and Organization, Localization, and Differential Splicing of Its Gene* , 1996, The Journal of Biological Chemistry.

[20]  J. Krischer,et al.  Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood , 1996 .

[21]  R. Pieters,et al.  In vitro chemosensitivity assessed with the MTT assay in childhood acute non-lymphoblastic leukemia. , 1995, Leukemia.

[22]  J. Harbott,et al.  Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. , 1995, Blood.

[23]  M. Spinella,et al.  Distinguishing between Folate Receptor-α-mediated Transport and Reduced Folate Carrier-mediated Transport in L1210 Leukemia Cells (*) , 1995, The Journal of Biological Chemistry.

[24]  R. Pieters,et al.  Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. , 1994, British Journal of Cancer.

[25]  M. Relling,et al.  Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia , 1994 .

[26]  G. Jansen,et al.  Importance of pharmacodynamics in the in vitro antiproliferative activity of the antifolates methotrexate and 10-ethyl-10-deazaaminopterin against human head and neck squamous cell carcinoma. , 1993, Biochemical pharmacology.

[27]  J. McGuire,et al.  Cross-resistance studies of folylpolyglutamate synthetase-deficient, methotrexate-resistant CCRF-CEM human leukemia sublines. , 1993, Leukemia.

[28]  J. Bertino,et al.  Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. , 1991, The Journal of biological chemistry.

[29]  R. Pieters,et al.  In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions , 1990 .

[30]  J. Schornagel,et al.  Methotrexate transport in variant human CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier. Selective effect on carrier-mediated transport of physiological concentrations of reduced folates. , 1990, The Journal of biological chemistry.

[31]  J. Shuster,et al.  Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis. , 1990, Blood.

[32]  H. Yamauchi,et al.  In vitro methotrexate polyglutamate formation is elevated in acute lymphoid leukemia cells compared with acute myeloid leukemia and normal bone marrow cells. , 1988, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society.

[33]  S. Rodenhuis,et al.  Development of an assay system for the detection and classification of methotrexate resistance in fresh human leukemic cells. , 1986, Cancer research.

[34]  J. Goldie,et al.  Heterogeneity in the specific activity and methotrexate sensitivity of dihydrofolate reductase from blast cells of acute myelogenous leukemia patients. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  D. Rodbard,et al.  Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. , 1985, The Journal of biological chemistry.

[36]  J. Bertino,et al.  Natural resistance to methotrexate in human acute nonlymphocytic leukemia. , 1977, Cancer treatment reports.

[37]  H. Gralnick,et al.  Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.

[38]  R. Bender.  Anti-folate resistance in leukemia: treatment with "high-dose" methotrexate and citrovorum factor. , 1975, Cancer treatment reviews.

[39]  H. Weiss,et al.  Acute monocytic leukemia. , 1946, The American journal of medicine.

[40]  Y. Assaraf,et al.  Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and-resistant leukemia cells. , 1997, Advances in enzyme regulation.

[41]  J. Bertino,et al.  Increased methotrexate polyglutamylation in acute megakaryocytic leukemia (M7) compared to other subtypes of acute myelocytic leukemia , 1997, Leukemia.

[42]  M. Waltham,et al.  Acute monocytic leukemia: a myeloid leukemia subset that may be sensitive to methotrexate. , 1995, Leukemia.

[43]  James T. Lin,et al.  Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease. , 1993, Leukemia.

[44]  B. Schweitzer,et al.  Basis for natural resistance to methotrexate in human acute non-lymphocytic leukemia. , 1991, Leukemia research.